drugset / Trial / NCT00240708

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

NCT00240708

Phase 3 Completed 205 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of risperidone, formulated as a long-acting injectable drug, compared with risperidone tablets in the treatment of patients with schizophrenia.

Timeline

Start
2004-06
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 2 mg Intramuscular
Subject Risperidone Other / unclassified 6 mg Intramuscular
Subject Risperidone Other / unclassified 25 mg Intramuscular
Subject Risperidone Other / unclassified 50 mg Intramuscular

Indications